Before starting DAAs therapy, subclinical hyperthyroidism, was found in 8 of 113 patients (7.1%) and 6 of them belonged to IFN-α group, while the remaining 2 were in the naïve group, see Table 1. The gene discussed is IFNA17; the disease is hyperthyroidism.